Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

April 14, 2023

In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.

April 14, 2023

A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.

April 12, 2023

With an overall 5-year survival rate of under 15% in patients with metastatic colorectal cancer, investigators have sought to parse mutational analyses to increase gains.

April 11, 2023

Brian I. Rini, MD, FASCO, discusses the investigation of immunotherapy following disease progression on previous immunotherapy in patients with relapsed/refractory renal cell carcinoma.

April 11, 2023

Adding patient-specific comorbidities improved the prognostic effect of risk prediction models for patients with primary or secondary myelofibrosis, according to findings from an assessment of data collected in Vanderbilt’s Synthetic Derivative and BioVU Biobank comprehensive electronic health record.

April 07, 2023

Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.

April 07, 2023

Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.

April 03, 2023

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.

March 27, 2023

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

March 27, 2023

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

March 22, 2023

Hematologists and oncologists are uniquely poised to aid in the identification of patients with hereditary hemorrhagic telangiectasia and assist in their care, and it is important for the practicing clinician to familiarize oneself with the symptoms of hereditary hemorrhagic telangiectasia to avoid overlooking the diagnosis.

March 20, 2023

A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.

March 20, 2023

Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.

March 16, 2023

Investigators are unclear about the factors driving the explosive growth in incidence of appendiceal cancer over the past 2 decades.

March 13, 2023

Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.

March 13, 2023

Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.

March 06, 2023

Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.

March 06, 2023

Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.

February 27, 2023

Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.

February 27, 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.